Last edition
News about "Lupin has entered into an agreement with Switzerla"
Lupin Partners with Sandoz to Market Biosimilar Ranibizumab Across Global Markets
Lupin has entered into an agreement with Switzerland-based Sandoz Group AG to market and commercialise its biosimilar ranibizumab in multiple international markets.
Lupin Has Entered Into An Agreement With Switzerla | 13/08/2025 | By Darshana | 172
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members